Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy (Q38101683)

28 August 2017

Chronic lymphocytic leukaemia--the role of the microenvironment pathogenesis and therapy (English)

1 reference

28 August 2017

0 references

0 references

1 reference

Manuel Rodriguez-Justo

object named as

Manuel Rodriguez-Justo

series ordinal

2

0 references

author name string

Alan D Ramsay

series ordinal

1

1 reference

PubMed ID

23617880

28 August 2017

language of work or name

English

0 references

publication date

25 April 2013

1 reference

British Journal of Haematology

28 August 2017

1 reference

28 August 2017

162

1 reference

28 August 2017

1

1 reference

28 August 2017

15-24

1 reference

B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol

28 August 2017

1 reference

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

21 January 2018

1 reference

MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment

21 January 2018

1 reference

CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease

21 January 2018

1 reference

Positioning the immune system: unexpected roles for alpha6-integrins

21 January 2018

1 reference

Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting

21 January 2018

1 reference

Targeting the microenvironment in chronic lymphocytic leukemia is changing the therapeutic landscape

21 January 2018

1 reference

Chemokine receptors and stromal cells in the homing and homeostasis of chronic lymphocytic leukemia B cells

21 January 2018

1 reference

Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.

21 January 2018

1 reference

Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

CXCR4 in clinical hematology

21 January 2018

1 reference

Immunomodulating drugs for chronic lymphocytic leukaemia

21 January 2018

1 reference

Lenalidomide alone and in combination for chronic lymphocytic leukemia

21 January 2018

1 reference

Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia

21 January 2018

1 reference

Pim kinase inhibitor, SGI-1776, induces apoptosis in chronic lymphocytic leukemia cells

21 January 2018

1 reference

Inflammation and survival pathways: chronic lymphocytic leukemia as a model system

21 January 2018

1 reference

Chronic lymphocytic leukemia: a tale of one or two signals?

21 January 2018

1 reference

B cell chronic lymphocytic leukemia: lessons learned from studies of the B cell antigen receptor

21 January 2018

1 reference

Gene expression profiling in chronic lymphocytic leukaemia

21 January 2018

1 reference

Lenalidomide in the treatment of chronic lymphocytic leukemia.

21 January 2018

1 reference

TAPP2 links phosphoinositide 3-kinase signaling to B-cell adhesion through interaction with the cytoskeletal protein utrophin: expression of a novel cell adhesion-promoting complex in B-cell leukemia

21 January 2018

1 reference

Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma

21 January 2018

1 reference

Mesenchymal stem cells: biology and potential clinical uses

21 January 2018

1 reference

CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?

21 January 2018

1 reference

Chronic lymphocytic leukaemia is driven by antigen-independent cell-autonomous signalling

21 January 2018

1 reference

Role of the extracellular and transmembrane domain of Ig-alpha/beta in assembly of the B cell antigen receptor (BCR).

21 January 2018

1 reference

First-line therapy with fludarabine compared with chlorambucil does not result in a major benefit for elderly patients with advanced chronic lymphocytic leukemia

21 January 2018

1 reference

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia

21 January 2018

1 reference

Macrophage migration inhibitory factor induces B cell survival by activation of a CD74-CD44 receptor complex

21 January 2018

1 reference

Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells

21 January 2018

1 reference

Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

21 January 2018

1 reference

The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib

21 January 2018

1 reference

Treatment of chronic lymphocytic leukemia requires targeting of the protective lymph node environment with novel therapeutic approaches.

21 January 2018

1 reference

The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia

21 January 2018

1 reference

Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia

21 January 2018

1 reference

Milatuzumab immunoliposomes induce cell death in CLL by promoting accumulation of CD74 on the surface of B cells

21 January 2018

1 reference

Selective, novel spleen tyrosine kinase (Syk) inhibitors suppress chronic lymphocytic leukemia B-cell activation and migration

21 January 2018

1 reference

Sorafenib induces cell death in chronic lymphocytic leukemia by translational downregulation of Mcl-1.

21 January 2018

1 reference

Comparison of the effects of two kinase inhibitors, sorafenib and dasatinib, on chronic lymphocytic leukemia cells

21 January 2018

1 reference

Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance

21 January 2018

1 reference

Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies

21 January 2018

1 reference

Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals

21 January 2018

1 reference

Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia

21 January 2018

1 reference

Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001

21 January 2018

1 reference

CXCR4 inhibitors: tumor vasculature and therapeutic challenges.

21 January 2018

1 reference

Regulation of B-cell fate by antigen-receptor signals

21 January 2018

1 reference

Notch-3 and Notch-4 signaling rescue from apoptosis human B-ALL cells in contact with human bone marrow-derived mesenchymal stromal cells

21 January 2018

1 reference

Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis

21 January 2018

1 reference

NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth

21 January 2018

1 reference

The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia

21 January 2018

1 reference

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

21 January 2018

1 reference

Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia

21 January 2018

1 reference

Contribution of alpha6 integrins to hematopoietic stem and progenitor cell homing to bone marrow and collaboration with alpha4 integrins

21 January 2018

1 reference

Occult B-cell lymphoproliferative disorders

21 January 2018

1 reference

Chronic lymphocytic leukemia: an update on biology and treatment.

21 January 2018

1 reference

Rituximab plus fludarabine and cyclophosphamide prolongs progression-free survival compared with fludarabine and cyclophosphamide alone in previously treated chronic lymphocytic leukemia.

21 January 2018

1 reference

The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia

21 January 2018

1 reference

Protein kinase C beta controls nuclear factor kappaB activation in B cells through selective regulation of the IkappaB kinase alpha

21 January 2018

1 reference

Involvement of RhoH GTPase in the development of B-cell chronic lymphocytic leukemia

21 January 2018

1 reference

A possible role for oxidation stress in lymphoid leukaemias and therapeutic failure

21 January 2018

1 reference

HS1 has a central role in the trafficking and homing of leukemic B cells

21 January 2018

1 reference

Notch, a unifying target in T-cell acute lymphoblastic leukemia?

21 January 2018

1 reference

Signaling pathways activated by the B-cell receptor in chronic lymphocytic leukemia.

21 January 2018

1 reference

Interactions between bone marrow stromal microenvironment and B-chronic lymphocytic leukemia cells: any role for Notch, Wnt and Hh signaling pathways?

21 January 2018

1 reference

The secret second life of an innocent chaperone: the story of CD74 and B cell/chronic lymphocytic leukemia cell survival

21 January 2018

1 reference

Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells

21 January 2018

1 reference

RhoH is critical for cell-microenvironment interactions in chronic lymphocytic leukemia in mice and humans

21 January 2018

1 reference

Distinctive features of "nurselike" cells that differentiate in the context of chronic lymphocytic leukemia

21 January 2018

1 reference

Identification of the TCL1 gene involved in T-cell malignancies

21 January 2018

1 reference

Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.

21 January 2018

1 reference

Disease burden of chronic lymphocytic leukaemia within the European Union

21 January 2018

1 reference

p53 and Notch signaling in chronic lymphocytic leukemia: clues to identifying novel therapeutic strategies

21 January 2018

1 reference

Chronic lymphocytic leukemia B cells of more than 1% of patients express virtually identical immunoglobulins

21 January 2018

1 reference

Treatment of hematologic neoplasms with new immunomodulatory drugs (IMiDs).

21 January 2018

1 reference

Emerging role of kinase-targeted strategies in chronic lymphocytic leukemia

21 January 2018

1 reference

PCI-32765: a novel Bruton's tyrosine kinase inhibitor for the treatment of lymphoid malignancies

21 January 2018

1 reference

The B-cell receptor signaling pathway as a therapeutic target in CLL.

21 January 2018

1 reference

Enzastaurin hydrochloride for lymphoma: reassessing the results of clinical trials in light of recent advances in the biology of B-cell malignancies

21 January 2018

1 reference

Inhibition of CXCR4 with the novel RCP168 peptide overcomes stroma-mediated chemoresistance in chronic and acute leukemias.

21 January 2018

1 reference

Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway

21 January 2018

1 reference

Stromal control of cystine metabolism promotes cancer cell survival in chronic lymphocytic leukaemia

21 January 2018

1 reference

Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukemia (B-CLL): Identification of markers with prognostic relevance

21 January 2018

1 reference

Mechanism of antigen-driven selection in germinal centres

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/BJH.12344

1 reference

28 August 2017

1 reference

PubMed ID

23617880